Please login to the form below

Not currently logged in


This page shows the latest Synthelabo news and features for those working in and with pharma, biotech and healthcare.

This month in 2000: The formation of GSK

This month in 2000: The formation of GSK

With the prospect of more receptive new leadership at SmithKline and a desire to stay ahead of a competitive industry fuelled by mergers – Astra and Zeneca and Sanofi and Synthélabo had

Latest news

  • A look back at Sanofi's merger with Synthélabo A look back at Sanofi's merger with Synthélabo

    based biopharma and former l'Oreal business Synthélabo, to create Sanofi- Synthélabo – then, the sixth largest pharma company in Europe. ... This growth continued, and it wasn't long before Sanofi- Synthélabo needed another merger to continue the

  • GE Healthcare's Graham Higson joins NDA Group

    Prior to that he spent five years at AstraZeneca as vice president and head of global regulatory affairs and before that served at Baxter, Synthelabo, CibaGeigy, Sandoz and Pfizer.

  • Sanofi-aventis rebrands as Sanofi

    Sanofi was originally formed in 1973, and merged with pharmaceutical company synthélabo in 1999. ... The company became sanofi-aventis in 2004 following the merger of sanofi-synthélabo and Aventis.

  • BioAlliance announces managerial changes

    His international experience in drug development, notably at Synthelabo, and his hospital practice are major assets for both the company and its commercial partners when preparing the next launches of

  • Pfizer buys out Exubera rights

    The agreement settles a spat over the experimental drug that has been ongoing since Sanofi Synthelabo's merger with Aventis in 2004.

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...